In this review:
Early alterations in bone development in MPS-II
Fortnightly IV laronidase regimen in MPS-I
Once- vs twice-weekly laronidase in MPS-I
Factors affecting adherence to ERT in MPS-II
Intrathecal ERT for children with MPS-II?
Elevated CSF GAGs in MPS-II with cognitive impairment
Stem cell transplant not recommended for I-cell disease
Decentralisation of ERT: experience from Brazil
Management of infusion-associated reactions
Immunological abnormalities in a family with MPS-II
Immunological evaluation mandatory in mucopolysccharidoses
Please login below to download this issue (PDF)